HOME >> BIOLOGY >> NEWS
New Findings On Receptor Regulation May Lead To Better Drugs For Diabetes

Promising new treatments for adult-onset diabetes hinge on the action of a single protein: a receptor that controls how cells respond to the hormone insulin.

By binding to the receptor, drugs known as thiazolidinediones (TZDs, for short) raise the body's sensitivity to insulin, allowing it to better regulate its blood sugar levels. Researchers at the University of Pennsylvania Medical Center have now revealed a key step in the regulation of this receptor -- information which could lead to safer and more effective medicines for diabetes. The group's findings appear in the November 26 issue of Nature.

The receptor, called PPAR-gamma, resembles several other receptor proteins that bind to small hormones. In fat cells, this receptor influences a variety of processes, including sugar metabolism and fat cell proliferation, by turning specific genes on and off. Chemicals that can bind to the receptor increase insulin's ability to lower blood sugar in the body.

That action is crucial to controlling adult-onset diabetes, which results not from a lack of insulin, but from the inability of cells to heed insulin's signals, says senior author Mitchell A. Lazar, MD, PhD, professor of medicine and genetics at Penn. More than 15 million Americans are thought to suffer from adult-onset diabetes, which typically develops after age 40. Half are unaware they have the disease, which is also a risk factor for heart disease and stroke.

"The reason this new family of drugs works to control adult-onset diabetes is because they bind to the receptor we worked with," says Lazar, who is also director of Penn's Diabetes Center. Rezulin, manufactured by Parke-Davis, is the only TZD currently on the market; several TZD compounds are in clinical trials and others are at earlier stages of development.

Unfortunately, as Lazar and coworkers discovered in 1996, when TZD activates PPAR-gamma, fat cells not only respond more readil
'"/>

Contact: Franklin Hoke or Rebecca Harmon
hokef@mail.med.upenn.edu
215-662-2560
University of Pennsylvania School of Medicine
25-Nov-1998


Page: 1 2 3

Related biology news :

1. Findings suggest need for new view of p53 cancer proteins interaction with DNA
2. Findings redefine mechanism of action of RNA helicase enzymes
3. Findings of novel nanoproperties in selenium produced by bacteria open new area of exploration
4. Findings could aid efforts to harness nature for making drugs
5. Findings offer clue to how molecule can both stimulate, suppress cell growth
6. Findings offer further understanding about growth and development in young male gymnasts
7. Findings in frog oocytes may help study of chromosome physiology
8. Findings aid understanding of neurodegenerative diseases
9. Findings show exceptional longevity runs in families
10. Findings give insight into how colon cells transform into precancerous polyps
11. Findings conclude sustained caffeine intake negates the benefits of creatine supplements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... ... Today CJ BIO announced the first in a series of Food Ingredient MasterClass webinars, ... revolutionizing ingredient mixes, nutritional content and flavor profiles across a range of savory foods ... AM (CDT) during SHIFT20, the virtual edition of the IFT Annual Meeting & Food ...
(Date:7/1/2020)... ... 2020 , ... Cure Glioblastoma, a registered 501(c)(3) nonprofit research ... adult brain cancer—announced today the appointments of its first Senior Fellows: John Boockvar, ... organization’s initiatives and overall vision. , "Senior Fellows are more than advisors; they ...
(Date:6/23/2020)... ... June 23, 2020 , ... First Aid Africa, ... a UK supplier and manufacturer of innovative portable renewable energy equipment, have announced ... fight against the COVID-19 pandemic in Zambia. , One of Renovagen’s FAST FOLD ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions ... that they have entered into a strategic partnership whereby Catalent will provide support ...
(Date:7/22/2020)... ... 22, 2020 , ... Join experts from Reed Tech , Gary Saner, ... a one hour live webinar on Thursday, August 13, 2020 at 11am ... and medical devices. Specifically, for medical devices, the NMPA has departments dealing with medical ...
(Date:7/18/2020)... ... 17, 2020 , ... dicentra , a leading Contract ... industries, is pleased to announce that Charles Galea has joined its clinical trials ... is an accomplished and results-driven sales executive with over 10 years of expertise ...
Breaking Biology Technology:
Cached News: